COEP
Coeptis Therapeutics, Inc.NASDAQHealthcare$11.98-2.42%ClosedMarket Cap: $42.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.87
P/S
30.14
EV/EBITDA
-3.02
DCF Value
$3.16
FCF Yield
-20.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-207.8%
Operating Margin
-956.9%
Net Margin
-611.1%
ROE
-78.8%
ROA
-42.0%
ROIC
-55.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $862.0K | -371.0% | $-2.0M | $-5.2M | $-0.29 | — |
| FY 2025 | $1.4M | -207.8% | $-13.0M | $-11.9M | $-2.81 | — |
| Q3 2025 | $237.4K | 81.0% | $-2.5M | $-159.4K | $-0.58 | — |
| Q2 2025 | $200.7K | 77.5% | $-4.5M | $-3.5M | $-0.95 | — |
| Q1 2025 | $62.9K | 28.2% | $-4.1M | $-3.1M | $-0.99 | — |
| Q4 2024 | $0.00 | -Infinity% | $-2.2M | $-3.0M | $4.09 | — |
| FY 2024 | $0.00 | -Infinity% | $-10.1M | $-10.9M | $-5.65 | — |
| Q3 2024 | $0.00 | -Infinity% | $-2.1M | $-1.8M | $-0.05 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.8M | $-3.0M | $-0.08 | — |
| Q1 2024 | $0.00 | -Infinity% | $-2.9M | $-3.0M | $-0.08 | — |
| Q4 2023 | $0.00 | -Infinity% | $-3.4M | $-3.8M | $-0.11 | — |
| FY 2023 | $0.00 | -Infinity% | $-21.5M | $-21.3M | $-0.83 | — |